Inozyme Pharma is a biotechnology company committed to developing novel therapeutics for the treatment of rare, life-threatening and devastating disorders of mineralization. The company was founded in 2017 with technology licensed from Yale University.
Inozyme’s lead program, INZ-701, is an enzyme replacement therapy in preclinical development and is indicated for treatment of ENPP1 deficiency. ENPP1 deficiency manifests as either generalized arterial calcification of infancy (GACI) type 1 or autosomal recessive hypophosphatemic rickets type 2 (ARHR2). ENPP1 deficiency is a rare, devastating disease resulting from decreased levels of serum PPi. PPi is essential for preventing harmful soft tissue calcification and for regulating normal bone mineralization. ENPP1 enzyme replacement therapy has proven to be successful in normalizing serum PPi, increasing survival and preventing pathogenic calcification in the animal models of ENPP1 deficiency.
For more information, please visit: www.inozyme.com.